Silo Pharma
SILO
6 hedge funds and large institutions have $183K invested in Silo Pharma in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.
154% more capital invested
Capital invested by funds: $72.3K → $183K (+$111K)
0.14% more ownership
Funds ownership: 0.05% → 0.18% (+0.14%)
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAIM
Financial Advocates Investment Management
Olympia,
Washington
|
+$71.9K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$59.8K |
| 3 |
State Street
Boston,
Massachusetts
|
+$30.4K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$10.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$17.5K |
| 2 |
FIM
FWL Investment Management
Dallas,
Texas
|
-$269 |
| 3 |
Morgan Stanley
New York
|
-$17 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FAIM
1
Financial Advocates Investment Management
Olympia,
Washington
| $93.5K | +$71.9K | +1,967 | +197% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $51.4K | +$59.8K | +1,636 | New |
|
|
3
State Street
Boston,
Massachusetts
| $26.2K | +$30.4K | +833 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $12K | +$10.5K | +288 | +369% |
|
|
WIM
5
Westside Investment Management
Santa Monica,
California
| $197 | – | – | – |
|
6
Wells Fargo
San Francisco,
California
| $42 | – | – | – |
|
|
7
UBS Group
Zurich,
Switzerland
| – | -$17.5K | -347 | Closed |
|
|
FIM
8
FWL Investment Management
Dallas,
Texas
| – | -$269 | -5 | Closed |
|
|
9
Morgan Stanley
New York
| – | -$17 | – | – |
|
SILO Hedge Fund Activity: Q1 2023 in Review
6 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Silo Pharma (SILO) for Q1 2023, worth a combined $183K — up 154% from $72.3K a quarter earlier.
Fund positioning in SILO was balanced in Q1 2023: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Financial Advocates Investment Management, adding an estimated $71.9K. The largest seller was UBS Group, exiting entirely with an estimated $17.5K sold.
- 6 institutional investors held Silo Pharma (SILO) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $183K of Silo Pharma stock for Q1 2023, up 154% quarter-over-quarter.
- 2 funds opened new Silo Pharma positions in Q1 2023 and 2 closed out, a net change of 0 holders.
- The largest Silo Pharma buyer in Q1 2023 was Financial Advocates Investment Management, an estimated $71.9K added.
- The largest Silo Pharma seller in Q1 2023 was UBS Group, an estimated $17.5K sold.
Based on aggregated 13F filings for Q1 2023.